Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection

Journal of Clinical Pharmacology

Volumn 41, Issue 12, 2001, Pages 1319-1328

  Zhao, Qinying ^a   Zhou, Honghui ^a   Pesco Koplowitz, Luana ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; HYDROXYITRACONAZOLE; ITRACONAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOTRANSFORMATION; CYCLODEXTRINS; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; MALE;

EID: 0035200596     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122012904     Document Type: Article

References (27)

1. Recent advances in cryptococcosis, candidiasis and coccidioidomycosis complicating HIV infection
2. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study
3. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients
4. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients
5. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis
6. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection
7. Optimisation of itraconazole therapy using target drug concentrations
8. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: Meeting report
9. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects
10. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
11. Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels
12. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers
13. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole
14. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers
15. Pharmacokinetics of itraconazole following oral administration to normal volunteers
16. Pharmacokinetics of oral antifungals and their clinical implications
17. Alterations in gastric acidity in patients infected with human immunodeficiency virus
18. Short report: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity
19. The pharmacokinetics of oral itraconazole in AIDS patients
20. Lack of interaction of antacid drug omeprazole on the bioavailability of itraconazole oral solution
21. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography
22. Determination of hydroxypropyl-beta-cyclodextrin in plasma and urine by size-exclusion chromatography with post-column complexation
23. Pharmacokinetics and safety of seven days' intravenous itraconazole followed by two weeks' oral itraconazole solution in patients with haematological malignancy
24. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units
25. Itraconazole and HIV protease inhibitors: An important interaction
26. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir